Abstract | PURPOSE: METHODS: Hundred and forty-five cases are included in the study, and levels of MMP/TIMP expressions are assessed in three tissue compartments (i.e., tumor, stroma and normal glands) with immunohistochemistry. RESULTS:
Matrix metalloproteinase-1 expression in tumor cells was associated with lower Gleason scores, pretreatment prostate-specific antigen levels and lower incidence of vascular, perineural and extracapsular invasions. Moreover, MMP-9 positivity and TIMP-2 expression in normal glands were correlated with lower Gleason patterns and early stage at presentation. Expression of MMP in tumor cells and the presence of TIMP-2 in normal glands were associated with better DFS. CONCLUSION: Variability of MMP/TIMP expressions from case to case makes it difficult to evaluate their impact on clinical outcome. However, these proteins might be new and promising targets for prostate cancer therapy in the future.
|
Authors | Ferhat Ozden, Caner Saygin, Didem Uzunaslan, Bulent Onal, Haydar Durak, Hilal Aki |
Journal | Journal of cancer research and clinical oncology
(J Cancer Res Clin Oncol)
Vol. 139
Issue 8
Pg. 1373-82
(Aug 2013)
ISSN: 1432-1335 [Electronic] Germany |
PMID | 23708302
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- TIMP2 protein, human
- Tissue Inhibitor of Metalloproteinase-2
- MMP9 protein, human
- Matrix Metalloproteinase 9
- MMP1 protein, human
- Matrix Metalloproteinase 1
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
(analysis)
- Carcinoma
(enzymology, mortality, pathology)
- Disease-Free Survival
- Humans
- Immunohistochemistry
- Kaplan-Meier Estimate
- Male
- Matrix Metalloproteinase 1
(analysis, biosynthesis)
- Matrix Metalloproteinase 9
(analysis, biosynthesis)
- Middle Aged
- Neoplasm Grading
- Neoplasm Staging
- Prognosis
- Prostatic Neoplasms
(enzymology, mortality, pathology)
- Tissue Array Analysis
- Tissue Inhibitor of Metalloproteinase-2
(analysis, biosynthesis)
|